Literature DB >> 16051229

Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression.

Sho-Ichi Yamagishi1, Masayoshi Takeuchi, Takanori Matsui, Kazuo Nakamura, Tsutomu Imaizumi, Hiroyoshi Inoue.   

Abstract

Advanced glycation end product (AGE)-their receptor (RAGE) and angiotensin II (AII) are implicated in diabetic retinopathy. However, a crosstalk between the two is not fully understood. In vivo, AGE injection stimulated RAGE expression in the eye of spontaneously hypertensive rats, which was blocked by an AII-type 1 receptor blocker, telmisartan. In vitro, AII-type 1 receptor-mediated reactive oxygen species generation elicited RAGE gene expression in pericytes through NF-kappaB activation. Further, AII augmented AGE-induced pericyte apoptosis, the earliest hallmark of diabetic retinopathy. Our present study may implicate a crosstalk between AGE-RAGE system and AII in diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16051229     DOI: 10.1016/j.febslet.2005.06.058

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  24 in total

Review 1.  Angiotensin II-related hypertension and eye diseases.

Authors:  Pablo Jesus Marin Garcia; Maria Encarna Marin-Castaño
Journal:  World J Cardiol       Date:  2014-09-26

Review 2.  Ascorbic acid repletion: A possible therapy for diabetic macular edema?

Authors:  James M May
Journal:  Free Radic Biol Med       Date:  2016-02-17       Impact factor: 7.376

3.  Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation.

Authors:  T Yoshida; S Yamagishi; K Nakamura; T Matsui; T Imaizumi; M Takeuchi; H Koga; T Ueno; M Sata
Journal:  Diabetologia       Date:  2006-09-27       Impact factor: 10.122

Review 4.  New standards in hypertension and cardiovascular risk management: focus on telmisartan.

Authors:  Domenico Galzerano; Cristina Capogrosso; Sara Di Michele; Antonio Galzerano; Paola Paparello; Diana Lama; Carlo Gaudio
Journal:  Vasc Health Risk Manag       Date:  2010-03-24

5.  Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy.

Authors:  Masayoshi Takeuchi; Jun-Ichi Takino; Sho-Ichi Yamagishi
Journal:  J Ophthalmol       Date:  2010-06-22       Impact factor: 1.909

6.  Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function.

Authors:  Antonia G Miller; Genevieve Tan; Katrina J Binger; Raelene J Pickering; Merlin C Thomas; Ram H Nagaraj; Mark E Cooper; Jennifer L Wilkinson-Berka
Journal:  Diabetes       Date:  2010-09-17       Impact factor: 9.461

7.  Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.

Authors:  Sho-Ichi Yamagishi; Nobutaka Nakamura; Mika Suematsu; Kuniyoshi Kaseda; Takanori Matsui
Journal:  Mol Med       Date:  2015-10-27       Impact factor: 6.354

8.  Ultrastructure of islet microcirculation, pericytes and the islet exocrine interface in the HIP rat model of diabetes.

Authors:  Melvin R Hayden; Poorna R Karuparthi; Javad Habibi; Guido Lastra; Kamlesh Patel; Chetan Wasekar; Camila Margarita Manrique; Ugur Ozerdem; Sameer Stas; James R Sowers
Journal:  Exp Biol Med (Maywood)       Date:  2008-07-18

9.  Lens epithelial cell apoptosis initiates diabetic cataractogenesis in the Zucker diabetic fatty rat.

Authors:  Junghyun Kim; Chan-Sik Kim; Eunjin Sohn; Hyojun Kim; Il-Ha Jeong; Jin Sook Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-17       Impact factor: 3.117

Review 10.  Advanced glycation end products (AGEs) and its receptor, RAGE, modulate age-dependent COVID-19 morbidity and mortality. A review and hypothesis.

Authors:  Durai Sellegounder; Parisa Zafari; Misagh Rajabinejad; Mahdi Taghadosi; Pankaj Kapahi
Journal:  Int Immunopharmacol       Date:  2021-05-24       Impact factor: 5.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.